2016

Differential involvement of hippocampal angiotensin 1 receptors in learning and memory processes in bulbectomized rats

Roman Tashev
Department of Pathophysiology, Medical University of Sofia, Bulgaria, romantashev@gmail.com

Margarita Ivanova
Department of Physiology and Pathophysiology, Medical University, M. Drinov str.55, Varna, 9000, Bulgaria,
msvelikova@yahoo.com

Stiliana Belcheva
Faculty of Pre-School and Primary School Education SU "Sv. Kl. Ohridsky", "Kl. Ohridski" str. 69A, Shipchenski Prohod Blvd 1574 Sofia, Bulgaria, sbelcheva@gmail.com

Iren Belcheva
Department of Behavioral Neurobiology, Institute of Neurobiology, Bulgarian Academy of Sciences, Acad. G. Bonchev St, Bl. 23, 1113 Sofia, Bulgaria, ibelcheva@gmail.com

Follow this and additional works at: http://scholar.valpo.edu/jmms

Part of the Animal Studies Commons, Medical Neurobiology Commons, Medical Pharmacology Commons, and the Neurosciences Commons

Differential involvement of hippocampal angiotensin 1 receptors in learning and memory processes in bulbectomized rats

Tashev E. Roman[1, 2], Margarita S. Ivanova[3], Stiliana P. Belcheva[1, 4], Iren P. Belcheva[1]

[1]Bulgarian Academy of Sciences, Institute of Neurobiology, Department of Behavior Neurobiology, [2]Department of Pathophysiology, Medical University of Sofia, [3]Medical University, Department of Physiology and Pathophysiology
[4]Faculty of Pre-School and Primary School Education SU Sv. Kl. Ohridsky

Abstract

There is conflicting evidence regarding the effect of AT1 receptor antagonists on learning and memory processes. The effects of angiotensin II and losartan administration into CA1 hippocampal area on the avoidance performance in olfactory bulbectomized (OBX) rats using active avoidance (shuttle box) test and passive avoidance (step through) test were investigated. Rats were microinjected unilaterally through implanted guide cannulas into the CA1 area of the dorsal hippocampus and the drugs were administered separately, 5 minutes before each training session. The microinjections of losartan into the left, but not the right CA1 hippocampal area improved the acquisition and retention of active and passive avoidance learning, thus suggesting dependence on the side of injection. The unilateral (left or right) administration of angiotensin II did not significantly affect the performance of OBX rats in the avoidance tasks. A differential distribution of the AT1 receptors in the left and right hemisphere could contribute for the asymmetry in the behavioral effects of the AT receptor antagonist.

Keywords: angiotensin II, losartan, learning, memory, asymmetry, hippocampus, olfactory bulbectomy

✉ Corresponding address: romantashev@gmail.com Department of Pathophysiology, Medical University of Sofia, 2 Zdrave Str., 1431 Sofia, Bulgaria

Introduction

The octapeptide angiotensin II (Ang II) is a potent effector hormone of the renin-angiotensin system (RAS). The brain has its own intrinsic RAS and most of its components are expressed in the central nervous system. The brain RAS includes the biologically active angiotensin peptides: Ang II, Ang III, Ang IV and Ang-(1-7) (1). Four receptor types have been proposed within the RAS: the Ang II type 1 and 2 receptors (AT1, AT2), Ang IV-specific receptor(AT4), and Ang-(1–7) selective receptor (2- 4). The AT1 and AT2 types are structurally similar, G-protein coupled receptors. The AT4 receptor is a protein, which is not G-protein-linked, while Ang-(1–7) exerts its actions via the G protein-coupled Mas receptor.

The hippocampus is a part of the limbic system, which is important for cognitive processes. Both the concentration of Ang II and the expression of angiotensin receptors are particularly high in the hippocampus and the CA1 hippocampal neurons are reported to be sensitive to Ang II (5, 6). Ang II being a part of the brain RAS, acts as a neurotransmitter or a neuromodulator. Increasing evidence supports the involvement of Ang II and its receptors in learning and memory processes, although the behavioral consequences apparently depend upon the methods, doses and location of the treatment (7-9). Previous studies have found behavioral asymmetries (in locomotor activity, anxiety, learning and memory) following microinjections of Ang II into the CA1 hippocampal area (9- 11).

The role of Ang II in brain pathology is poorly understood and not widely studied. Ang II has been suggested to participate in the pathophysiology of stress, Alzheimer's disease and depression. The first evidence that brain RAS may be involved in depressive disorder was observed in hypertensive patients undergoing captopril treatment (12). Investigations demonstrated that high angiotensin-converting enzyme activity led to high Ang II formation, which was associated with depression, hypothalamic-pituitary axis hyperactivity and anxiety (13-15). It was found that the blockage of angiotensin II synthesis with angiotensin-converting enzyme inhibitors (ACEI) in transgenic rats with high production of brain Ang II reduces the increased anxiety (16, 17). There is increasing evidence indicating beneficial effects of angiotensin II receptor blockers (ARBs) in brain disorders such as stroke, Alzheimer's disease, depression and stress (18). In an experimental study, the AT1 antagonist losartan improved depression-like behavior in mice, as determined by the forced swim test (19). Clinical research demonstrated that the treatment with ARBs decreases anxiety and depression in patients (20, 21). The ACEI led to similar therapeutic effects - improved the efficacy of antidepressants and decreased anxiety and depression in normotensive rats (22, 23).

Olfactory bulbectomy (OBX) provides a well-validated animal model of depression. It is considered most suitable for studying the neurochemical mechanisms underlying the pathophysiology of depression. Bilateral removal of the olfactory bulbs in rats induces a syndrome of behavioral deficits that reflect a disruption of cortical and limbic regions, accompanied by neurochemical, endocrine and immune alterations, reminiscent of symptoms of human depression (24, 25). OBX leads to extensive cognitive impairments, with deficits in learning and memory (24, 26, 27). Borre et al. and Douma et al. have suggested that OBX in rats can serve also as an animal model of neurodegeneration (28, 29). According to Yehuda and Rabinovitz, OBX mimics a complex of Alzheimer's symptoms, including cognitive decline, increased locomotor activity, decreased food intake, etc. (30). The neurodegeneration of the septo-hippocampal cholinergic pathways (31), which accompany memory impairments and the elevation of *amyloid* beta level in the brain (32) also point to the usefulness of OBX as an animal model of Alzheimer's disease.

Bearing in mind the above considerations, the aim of our study was to examine the effects of Ang II and the AT1 receptor antagonist losartan on learning and memory processes after unilateral application into CA1 hippocampal area in OBX rats.

Materials and methods

Animals

Male Wistar rats (200 – 220 g, 2 month old at the time of surgery) were housed individually in polypropylene boxes with free access to food and water. The animals were maintained in a constant temperature environment (22 ± 2°C) on a 12h light/dark cycle (lights on at 6.00 am). The behavior experiments were carried out between 10:00 am and 1:00 pm. After the testing procedure, the rats were returned to their respective home cages.

The experiments were performed according to the "Rules for care and experiments on laboratory animals" of the Ethics Committee of the Institute of Neurobiology, Bulgarian Academy of Sciences. All efforts were made to minimize animal suffering and reduce the number of animals used in the study.

Surgical procedures

Bilateral olfactory bulbectomy was carried out according to the method described by Kelly et al. (24). Seven days after bilateral olfactory bulbectomy a cannula was surgically implanted into the CA1 hippocampal area as described previously (9).

Behavioral methods

The animals were tested in a two-way active avoidance test (shuttle box) and a passive

avoidance test (step-through) as described previously (7).

Statistical analysis

Separate two-factor analysis of variance (ANOVA) was used to analyze the data obtained for the number of avoidances (shuttle-box) in the learning test (1st and 2nd training day) and the memory test (24 h after the 2nd training day) between subject factors: drug (three levels: Ang II, losartan or saline) and side of injection (two levels: left and right). ANOVA data were analyzed further by post-hoc Student-Newman–Keuls (SNK). Analysis of the passive avoidance data was performed using $\chi 2$ tests.

Results

Shuttle box test

The bilateral removal of the olfactory bulbs resulted in an impairment of the learning and memory in the active avoidance task (shuttle box).The number of avoidances of rats with developed depression was significantly lower as compared to the sham-operated controls on the 1st training day (P $\leq$ 0.001), 2nd training day (P $\leq$ 0.001) and on the retention test (P $\leq$ 0.001) (Fig. 1A, B, C).Two way ANOVA demonstrated significant effects for the factors "drug" (Ang II and losartan) on the number of avoidances (F$_{2,35}$= 13,819, P<0.001)and "side" of injection (F$_{1,35}$= 8.533, P$\leq$ 0.04) on the 1sttraining day. There was also significant interaction between "drug"×"side"

of injection (F$_{2,\ 35}$=8,402, P$\leq$0.001). On the 2ndtraining day ANOVA demonstrated significant effects for the factors "drug" (F$_{2,35}$ = 32,439, P $\leq$ 0.001), "side" (F$_{1,35}$ = 19.756, P $\leq$ 0.001) and a significant interaction between the factors "drug"× "side " (F$_{1,35}$ = 18.756, P $\leq$ 0.001). At the retention test ANOVA revealed a significance for "drug" (F$_{2,35}$ = 25.833, P $\leq$ 0.001), side of injection (F$_{1,35}$ = 15,873, P $\leq$ 0.001) and a significant interaction between "drug" × "side" (F$_{2,35}$ = 18,373; P $\leq$ 0.001).

Post-hoc SNK comparisons demonstrated that losartan infused into CA1 area produced significantly greater number of avoidances when injected into the left CA1 area on 1st day (P $\leq$ 0.001), 2nd day (P $\leq$ 0.001) and at the retention test (P $\leq$ 0.001), as compared to the respective saline-treated OBX-controls (Fig. 1A, B, C). Microinjected into the right side, losartan did not affect significantly the number of avoidances on the training days and at the retention test (Fig. 1A, B, C).Upon left-side or right-side administration, Ang II did not significantly affect the number of avoidances, as compared to the respective OBX saline-treated controls during the whole experimental period(Fig. 1A, B, C).

The unilateral injection of losartan showed a clear lateralized improvement of learning and memory. Microinjected into the left CA1 area losartan increased significantly the number of avoidances as compared to the right-side

42

injections: on the 1st training day ($P \leq 0.001$), on the 2nd day ($P \leq 0.001$) and at the retention test($P \leq 0.001$) (Fig. 1A, B, C).

Step through test

One way ANOVA on the latent time of OBX rats showed a significant effect on the retention tests: on the 3rd h after training ($F_{1,11} = 155,702$; $P \leq 0.001$) and on the 24th after training ($F_{1,11} = 218,256$; $P \leq 0.001$). At the passive avoidance task, bulbectomized rats demonstrated a significant decrease of the latent time on the retention tests: on the 3rd h ($P \leq 0.001$) and on the 24th ($P \leq 0.001$) as compared to the sham-OBX group. The number of OBX rats fulfilling the learning criteria diminished to 0%,as compared to the sham operated controls which reached50%learning criteria on the 3^{rd}h and 63% on the 24th h (Fig. 1A, B). Separate two way ANOVA demonstrated significant effects of the factors "drug"($F_{2,47} = 45,014$; $P \leq 0.001$) and "side"($F_{1,47} = 42,103$, $P \leq 0.04$)for the 3^{rd}hThere was also significant interaction between "drug"×"side" of injection ($F_{2,47}=34,715$, $P \leq 0.001$). At the retention test ANOVA showed significance for "drug" ($F_{2,47} = 150,410$, $P \leq 0.001$), "side" ($F_{1,47} = 115,394$, $P \leq 0.001$), as well as a significant interaction between "drug" × "side" ($F_{2,47} = 118,530$; $P \leq 0.001$).

Post hoc test showed that the microinjection of losartan into the left CA1 area prolonged the latency time on the 3^{rd}h ($P \leq 0.001$) and on the 24th h ($P \leq 0.001$) and increased the percentage of the rats that reached the learning criteria on the 3^{rd}h (50%)and on the 24th h(63%).Losartan infused into the right side did not affect the performance of the OBX rats in the step-through task (Fig. 2A, B).The injection of losartan into the left CA1 area increased significantly the latent time on the 3^{rd}h ($P \leq 0.001$) and 24th h ($P \leq 0.001$) as compared to the right-side infusions (Fig. 2A, B). The effect of Ang II administered unilaterally (left- or right side) did not differ significantly from the respective saline treated OBX controls (Fig. 2A, B).

Discussion

The bilateral olfactory bulbectomy markedly impaired the performance of rats in both avoidance tasks compared to the sham-operated controls, as has been reported previously (24, 27). Our results showed a lateralized ameliorating effect of the AT1 receptor antagonist losartan on learning and memory deficits in OBX rats. The microinjections of losartan into the left but not the right CA1 hippocampal area improved the acquisition and retention of active and *passive avoidance* learning, thus suggesting dependence on the side of injection. In addition, the unilateral (left or right) administration of angiotensin II did not affect significantly the performance of OBX rats in the avoidance tasks.

Studies have shown controversial results about the effects centrally administered AngII on learning and memory processes. In the avoidance paradigms, used to evaluate learning and memory

of rodents, it has been observed that intracerebroventricular (i.c.v.) injection of Ang II impairs (34), improves (35-37), or has no effect (38) on the cognitive performance. The administration of Ang II into CA1 hippocampal area in a step-down inhibitory avoidance task produced a dose-dependent amnesic effect, which was blocked by the AT2 receptor antagonist, PD 123319, but not by the AT1 receptor antagonist losartan (39, 40). The conflicting results about the cognitive effects of Ang II can be explained by the fact that these effects are very sensitive to the different methodological approaches (time interval between the injection of Ang II and the performing of the test, type of administration, differences in dosage, duration of treatment, number of training sessions, and type of memory task evaluated).

Concerning the type of receptors involved in the effects of Ang II on cognitive processes, data are contradictory too. Braszko reported that both AT1 and AT2 receptors may contribute to the effects of Ang II in passive avoidance, object recognition and active avoidance tests, with an exception of lack of influence of AT1 receptor inhibition on active avoidance acquisition (41), while other authors (37, 42) observed no effect of centrally applied losartan on active avoidance tests.

By comparing the effect of captopril (ACEI) and losartan (a selective AT_1 receptor antagonist) in an active avoidance task, Raghavendra et al. found that both drugs were equally effective in enhancing retention of memory when administered prior to training. Hence, it was concluded that the decrease in endogenous Ang II activity in the brain might result in improved cognitive performance (43).

There are many reports about the beneficial effects of AT1 blockers in different *experimental models* of learning and *memory impairments*. DeNoble et al. showed that the impaired performance on a passive avoidance task in rats treated i.c.v. with renin could be offset with ACEI treatment, or by the application of the AT1 receptor antagonists (44). Orally administered telmisartan (AT1 receptor blocker) improved spatial learning and memory in a type 1 diabetic mouse model, streptozotocin-induced diabetic mice (45), while pretreatment with a non-hypotensive dose of telmisartan significantly inhibited cognitive decline in an experimental model of Alzheimer disease (46). Inaba et al. demonstrated that olmesartan (another AT1 blocker) diminished the cognitive alterations observed ina shuttle-box avoidance task for the human renin and human angiotensinogen gene chimeric transgenic mice and suggested that continuous activation of the brain RAS impairs cognitive function via stimulation of AT1 receptor (47). Clinical data with Ang II antagonists tend to support experimental findings. It has been shown that losartan improves cognitive functions in hypertensive patients as well as in normotensive adults (48, 49).

Our results showed no effects of Ang II on the avoidance behavior of OBX rats. Previously, using the same experimental protocol, Belcheva et al. reported that Ang II infused into CA1 area enhanced acquisition and retention in a two-way active avoidance test (9). The bilateral removal of the olfactory bulbs results in neurodegeneration in the projection areas of the bulbs such as cortex, amygdala and hippocampus (25). Although data are lacking about the expression of RAS components in the brain of OBX rats, the neurodegenerative changes might be accompanied with abnormalities in RAS in different brain regions, similarly to the observed alterations on AT receptors in patients with neurodegenerative disorders (50, 51). It could be suggested that the neurodegenerative changes in the hippocampus and the following compensatory neuronal reorganization could explain the lack of effects of angiotensin II on the performance of OBX rats.

The improvement of memory deficits after injection of losartan into CA1 area in OBX rats may be related to its neuroprotective, anti-inflammatory and anti-oxidant effects. Neurodegenerative changes, inflammation and oxidative stress were found to play role in the etiology of OBX-induced depression. Increased production of oxygen reactive species, saturation of antioxidant enzymes, lipid peroxidation and generation of pro-inflammatory cytokines in the brain of OBX rats have been reported (52- 55).

Angiotensin II type 1 (AT1) receptor blockers have shown powerful neuroprotective effects in vivo (56, 57). The latest research provided evidence that ARBs may protect the brain from different types of injury resulting in parenchyma inflammation and neuronal damage. Beneficial effects on memory functions for the AT1 receptor blockers have been demonstrated in traumatic animal models. For example, candesartan treatment reduced the lesion volume after controlled cortical impact injury on mice and improved performance in the Morris water maze 4 weeks after injury (58). The AT1 blockers candesartan and telmisartan exhibited neuroprotective and anti-inflammatory effects in different models of brain injury in rodents (58- 61). The systemic administration of candesartan decreased the acute brain inflammatory response to a bacterial endotoxin lipopolysaccharide and reduced the inflammatory reaction by decreasing the production of cytokines and other inflammatory factors in the brain cortex (62, 63). The anti-inflammatory effects were widespread, occurring in many limbic areas such as hypothalamus, prefrontal cortex, hippocampus, and amygdala.

Left–right asymmetries of brain and behavior are widespread among both vertebrates and invertebrates. Knowledge of the bilateral distribution of a system in brain is important to appropriately understand how it functions in health

and pathology. Data have accumulated concerning anatomical, functional and neurochemical asymmetries in the rat brain. The research on the impact of hippocampal left–right asymmetry on higher-order brain functions using "split-brain" mice have shown that the usage of the right hippocampus improves the accuracy of spatial memory, while performance of other hippocampus-dependent tasks (fear conditioning) was not influenced by the laterality of the hippocampus (64). Recently, a dissociation of hippocampal long-term memory function between hemispheres has been reported, suggesting that memory is routed via distinct left–right pathways within the mouse hippocampus (65).

Other evidence regarding the lateralization in the expression of different components of RAS has been provided by the research of Wu et al., who found asymmetrical distribution of angiotensinase activity in the amygdala, hippocampus and prefrontal cortex of the rat (66). The aminopeptidases (APs) termed angiotensinases are involved in the metabolism of angiotensin peptides. In the hippocampus, there was a left predominance for AlaAP, CysAP and AspAP activities, while GluAP predominated in the right hippocampus (66, 67). It was also suggested that the asymmetric activity of angiotensinases in the rat hippocampus might be associated with both the direction and the intensity of behavioral lateralization as expressed by paw preference (66).

Our results are in line with the reports about asymmetry in the effects of drugs acting on angiotensin receptors. Belcheva et al. observed lateralization in the effects of angiotensin II, injected into the CA1 area of rats, where left-side administration enhanced acquisition and retention in an active avoidance task (9). Previous research of our laboratory also demonstrated lateralized memory enhancing effects of Ang IV and Ang II after pretreatment with losartan in the CA1 area (7, 68).

Based on the above-mentioned findings, we suggest that the lateralized ameliorative effect of losartan on learning and memory in OBX rats could be attributed to a hemispheric asymmetry in the components of the hippocampal RAS, including the expression and/or activity of different peptides, enzymes and receptors.

In conclusion, our study demonstrated lateralized *beneficial effects* of losartan, injected into the CA1 hippocampal area, on learning and *memory deficits* induced by the olfactory bulbectomy in rats. Ang II did not affect the behavior of OBX rats tested in the avoidance paradigms. A differential distribution of the AT1 receptors in the left and right hemisphere could contribute for the asymmetry in the behavioral effects of the AT receptor antagonist.

References

1) von Bohlen und Halbach O, Albrecht D. The CNS renin-angiotensin system. *Cell Tissue Res.* 2006; 326(2): 599-616.

2) de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. *Pharmacol Rev.* 2000; 52(3): 415-472.

3) Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, et al. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. *Proc. Natl. Acad. Sci USA*. 2003; 100(14): 8258–8263.

4) Wright JW, Harding JW. Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions. *Regul Pept*. 1995; 59(3): 269–295.

5) von Bohlen und Halbach O, Albrecht D. Mapping of angiotensin AT1 receptors in the rat limbic system. *Regul Pept*. 1998; 78(1-3): 51-6.

6) Wright JW, Harding JW. Brain renin-angiotensin--a new look at an old system. *Prog Neurobiol*. 2011; 95(1): 49-67.

7) Tashev R, Stefanova M. Hippocampal asymmetry in angiotensin II modulatory effects on learning and memory in rats. *Acta Neurobiol Exp.* 2015; 75(1): 48-59.

8) de Souza FA, Sanchis-Segura C, Fukada SY, de Bortoli VC, Zangrossi H Jr, de Oliveira AM. Intracerebroventricular effects of angiotensin II on a step-through passive avoidance task in rats. *Neurobiol Learn Mem.* 2004; 81(1): 100-3.

9) Belcheva I, Ternianov A, Georgiev V. Lateralized learning and memory effects ofangiotensin II microinjected into the rat CA1 hippocampal area. *Peptides.* 2000; 21(3): 407-411.

10) Belcheva I, Chobanova M, Georgiev V. Differential behavioral effects of angiotensin II microinjected unilaterally into the CA1 hippocampal area. *Regul Pept.* 1998; 74(2-3): 67–71.

11) Belcheva I, Georgiev V, Chobanova M, Hadjiivanova C. Behavioral effects of angiotensin II microinjected into CA1 hippocampal area. *Neuropeptides.* 1997; 31(1): 60–4.

12) Germain L, Chouinard G. Captopril treatment of major depression with serial measurements of blood cortisol concentrations. *Biol Psychiatry* 1989; 25(4): 489–493.

13) Bondy B, Baghai TC, Zill P, Schule C, Eser D, Deiml T, Zwanzger P, Ella R, Rupprecht R. Genetic variants in the angiotensin I-converting-enzyme (ACE) and angiotensin II receptor (AT1) gene and clinical outcome in depression. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 2005; 29(6): 1094–1099.

14) Heck A, Lieb R, Ellgas A, Pfister H, Lucae S, Erhardt A, Himmerich H, Horstmann S, Kloiber S, Ripke S, Müller-Myhsok B, Bettecken T, Uhr M, Holsboer F, Ising M. Polymorphisms in the angiotensin-converting enzyme gene region predict coping styles in healthy adults and depressed patients. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 2009; 150B(1): 104–114.

15) López-León S, Janssens AC, Tiemeier H, Hofman A, Aulchenko YS, Snijders PJ, Claes S, Oostra BA, van Duijn CM. Angiotensinogen M235T polymorphism and symptoms of depression in a population-based study and a family-based study. *Psychiatr. Genet.* 2008; 18(4): 162–166.

16) Wilson W, Voigt P, Bader M, Marsden CA, Fink H. Behaviour of the transgenic (mREN2)27 rat. *Brain Res.* 1996; 729(1): 1–9.

17) Krsková L, Vrabcová M, Zeman M. Effect of melatonin on exploration and anxiety in normotensive and hypertensive rats with high activity of renin-angiotensin system. *Neuro Endocrinol. Lett.* 2007; 28(3): 295–301.

18) Saavedra JM, Sánchez-Lemus E, Benicky J. Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: therapeutic implications. *Psychoneuroendocrinology.* 2011; 36(1): 1–18.

19) Gard PR, Mandy A, Sutcliffe MA. Evidence of a possible role of altered angiotensin function in the treatment, but not etiology, of depression. *Biol. Psychiatry*. 1999; 45(8): 1030–1034.

20) Weber MA. Angiotensin-II receptor blockers for hypertension and heart failure: quality of life and outcomes. *Manag Care Interface*. 2005; 18(2): 47–54.

21) Pavlatou MG, Mastorakos G, Lekakis I, Liatis S, Vamvakou G, Zoumakis E, Papassotiriou I, Rabavilas AD, Katsilambros N, Chrousos GP. Chronic administration of an angiotensin II receptor antagonist resets the hypothalamic-pituitary-adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: preliminary results. *Stress*. 2008; 11(1): 62–72.

22) Braszko JJ, Karwowska-Polecka W, Halicka D, Gard PR. Captopril and enalapril improve cognition and depressed mood in hypertensive patients. *J. Basic Clin. Physiol. Pharmacol.* 2003; 14(4): 323–343.

23) Hertzman M, Adler LW, Arling B, Kern M. Lisinopril may augment antidepressant response. *J. Clin. Psychopharmacol.* 2005; 25(6): 618–620.

24) Kelly JP, Wrynn AS, Leonard BE. The olfactory bulbectomized rat as a model of depression: An update. *Pharmacol Ther.* 1997; 74(3): 299-316.

25) Song C, Leonard BE. The olfactory bulbectomized rat as a model of depression. *Neurosci Biobehav Rev.* 2005; 29(4-5): 627–647.

26) Mucignat-Caretta C, Bondí M, Caretta A. Time course of alterations after olfactory bulbectomy in mice. *Physiol Behav.* 2006; 89(5): 637-43.

27) Tashev R, Ivanova M, Toromanov T, Marinov M, Belcheva S, Belcheva I. Olfactory bulbectomy impairs active and passive avoidance learning in rats. *Compt. Rend. Acad. Bulg. Sci.* 2010; 63(4): 617-620.

28) Borre Y, Bosman E, Lemstra S, Westphal KG, Olivier B, Oosting RS. Memantine partly rescues behavioral and cognitive deficits in an animal model of neurodegeneration. *Neuropharmacology.* 2012; 62(5-6): 2010–7.

29) Douma TN, Borre Y, Hendriksen H, Olivier B, Oosting RS. Simvastatin improves learning and memory in control but not in olfactory bulbectomized rats. *Psychopharmacology.* 2012; 216(4): 537–44.

30) Yehuda S, Rabinovitz S. Olfactory bulbectomy as a putative model for Alzheimer': The protective role of essential fatty acids. *Pharma Nutrition* 2014; 2(1): 12–18.

31) Hozumi S, Nakagawasai O, Tan-No K, Niijima F, Yamadera F, Murata A, Arai Y, Yasuhara H, Tadano T. Characteristics of changes in cholinergic function and impairment of learning and memory-related behavior induced by olfactory bulbectomy. *Behav Brain Res.* 2003; 138(1): 9-15.

32) Aleksandrova I, Kuyichkin V, Kashparov I, Medvinskaya N, Nesterova I, et al. Increased level of beta-amyloid in the brain of bulbectomized mice. *Biochemistry (Mosc).* 2004; 69(2): 176-80.

33) Pellegrino L, Cushman A. A stereotaxic atlas of the rat brain. Appleton-Century-Crofts, New York, 1967.

34) Morgan JM, Routtenberg A. Ang II injected into the neostriatum after learning disrupts retention performance. *Science*. 1977; 196(4285): 87-9.

35) Braszko JJ, Wiœniewski K. Effect of angiotensin II and saralasin on motor activity and the passive avoidance behavior of rats. *Peptides*. 1988; 9(3): 475-9.

36) Braszko JJ. AT(2) but not AT(1)receptor antagonism abolishes angiotensin II increase of the acquisition of conditioned avoidance responses in rats. *Behavioural Brain Research 2002;* 131(1-2): 79-86.

37) Karwowska-Polecka W, Kułakowska A, Wiśniewski K, Braszko JJ. Losartan influences behavioural effects of angiotensin II (3-7) in rats. *Pharmacol Res*. 1997; 36(4): 275-83.

38) Wright J, Miller-Wing A, Shaffer M, Higginson C, Wright D, Hanesworth J, Harding J. Angiotensin II(3-8) (ANG IV) hippocampal binding: potential role in the facilitation of memory. *Brain Res Bull*. 1993; 32(5): 497-502.

39) Kerr D, Bevilaqua L, Bonini J, Rossato J, Köhler C, Medina J, Izquierdo I, Cammarota M. Angiotensin II blocks memory consolidation through an AT2 receptor-dependent mechanism.

Psychopharmacology (Berl). 2005; 179(3): 529-35.

40) Bonini JS, Bevilaqua LR, Zinn CG, Kerr DS, Medina JH, Izquierdo I, Cammarota M. Angiotensin II disrupts inhibitory avoidance memory retrieval. *HormBehav*. 2006; 50(2): 308-13.

41) Braszko J. The contribution of AT1 and AT2 angiotensin receptors to its cognitive effects. *Acta Neurobiol Exp (Wars)*. 1996; 56(1): 49-54.

42) Kułakowska A, Karwowska W, Wiśniewski K, Braszko JJ. Losartan influences behavioural effects of angiotensin II in rats. *Pharmacological Research*. 1996; 34(3–4): 109-15.

43) Raghavendra V, Chopra K, Kulkarni SK. Comparative studies on the memory enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm. *Neuropeptides*. 2001; 35(1): 65-9.

44) DeNoble VJ, DeNoble KF, Spencer KR, Chiu AT, Wong PC, Timmermans BM. Non-peptide angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor: effect on a rennin induced deficit of a passive avoidance response in rats. *Brain Res*. 1991; 561(2): 230-5.

45) Du GT, Hu M, Mei ZL, Wang C, Liu GJ, Hu M, Long Y, Miao MX, Chang Li J, Hong H. Telmisartan treatment ameliorates memory deficits in streptozotocin-induced diabetic mice via attenuating cerebral amyloidosis. *J Pharmacol Sci.* 2014; 124(4): 418-26.

46) Mogi M, Li JM, Tsukuda K, Iwanami J, Min LJ, Sakata A, Fujita T, Iwai M, Horiuchi M. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. *Biochem Biophys Res Commun*. 2008; 375(3): 446-9.

47) Inaba S, Iwai M, Furuno M, Tomono Y, Kanno H, Senba I, Okayama H, Mogi M, Higaki J, Horiuchi M. Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice. *Hypertension*. 2009; 53(2): 356-62.

48) Tedesco MA, Ratti G, Mennella S, Manzo G, Grieco M, Rainone AC, Iarussi D, Iacono A. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. *Am J Hypertens*. 1999; 12: 1130–1134.

49) Fogari R, Mugellini A, Zoppi A, Derosa G, Pasotti C, Fogari E, Preti P. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. *Journal of Human Hypertension.* 2003; 17(11): 781-785.

50) Ge J, Barnes NM. Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders. *Eur J Pharmacol*. 1996; 297(3): 299-306.

51) Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C, Müller-Spahn F. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. *Neurobiol Aging*. 2001; 22(4): 541-546.

52) Tasset I, Medina FJ, Peña J, Jimena I, Del Carmen Muñoz M, et al. Olfactory bulbectomy induced oxidative and cell damage in rat: protective effect of melatonin. *Physiol Res*. 2010; 59(1): 105-112.

53) Myint AM, Steinbusch HW, Goeghegan L, Luchtman D, Kim YK, Leonard BE. Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomized rat model of depression. *Neuroimmunomodulation* 2007; 14(2): 65-71.

54) Rinwa P, Kumar A. Quercetin suppress microglial neuroinflammatory response and induce antidepressant-like effect in

olfactory bulbectomized rats. *Neuroscience* 2013; 255: 86-98.

55) Song C, Zhang XY, Manku M. Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment. *J Neurosci*. 2009; 29(1): 14-22.

56) Saavedra J. Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders. *Clin. Sci. (Lond).* 2012; 123(10): 567–590.

57) Wang J, Pang T, Hafko R, Benicky J, Sanchez-Lemus E, Saavedra JM. Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPARγ activation. *Neuropharmacology.* 2014; 79: 249-61.

58) Villapol S, Yaszemski AK, Logan TT, Sánchez-Lemus E, Saavedra JM, Symes AJ. Candesartan, an angiotensin II AT$_1$-receptor blocker and PPAR-γ agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice. *Neuropsychopharmacology.* 2012; 37(13): 2817-29.

59) Timaru-Kast R, Wyschkon S, Luh C, Schaible EV, Lehmann F, Merk P, Werner C, Engelhard K, Thal SC. Delayed inhibition of angiotensin II receptor type 1 reduces secondary brain damage and improves functional recovery after experimental brain trauma. Crit Care Med. 2012; 40(3): 935–944.

60) Kasahara Y, Taguchi A, Uno H, Nakano A, Nakagomi T, Hirose H, Stern DM, Matsuyama T. Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia. *Brain Res*. 2010; 1340: 70-80.

61) Jung K, Chu K, Lee S, Kim S, Song E, Kim E, Park D, Sinn D, Kim J, Kim M, Roh J. Blockade of AT1 receptor reducesapoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. *J Pharmacol Exp Ther*. 2007; 322(3): 1051-8.

62) Benicky J, Sánchez-Lemus E, Honda M, Pang T, Orecna M, Wang J, Leng Y, Chuang DM, Saavedra JM. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. *Neuropsychopharmacology*. 2011; 36(4): 857-70.

63) Benicky J, Sánchez-Lemus E, Pavel J, Saavedra JM. Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. *Cell MolNeurobiol*. 2009; 29(6-7): 781-92.

64) Shinohara Y, Hosoya A, Yamasaki N, Ahmed H, Hattori S, Eguchi M, Yamaguchi S, Miyakawa T, Hirase H, Shigemoto R. Right-hemispheric dominance of spatial memory in split-brain mice. *Hippocampus.* 2012; 22(2): 117-21.

65) Shipton OA, El-Gaby M, Apergis-Schoute J, Deisseroth K, Bannerman DM, Paulsen O, Kohl MM. Left–right dissociation of hippocampal memory processes in mice. *Proc Natl AcadSci USA.* 2014; 111(42): 15238–15243.

66) Wu HM, Wang C, Wang XL, Wang L, Chang CW, Wang P, Gao GD. Correlations between angiotensinase activity asymmetries in the brain and paw preference in rats. *Neuropeptides.* 2010; 44(3): 253-9.

67) Banegas I, Prieto I, Alba F, Vives F, Araque A, Segarra AB, Durán R, de Gasparo M, Ramírez M. Angiotensinase activity is asymmetrically distributed in the amygdala, hippocampus and prefrontal cortex of the rat. *Behav Brain Res.* 2005; 156(2): 321-6.

68) Tashev R, Ivanova M. Lateralized hippocampal effects of angiotensin IV on learning and memory in rats. *Compt. Rend L'Acad Bulg Sci.* 2015; 68(10): 1309-1316.

Figure captions

Fig. 1 (A, B, C). Effects ofAng II (0,5 μg) and losartan (100 μg) microinjected unilaterally into the left or right CA1 hippocampal area of OBX rats on the number of avoidances (shuttle box). **A)** 1st training day; **B)** 2nd training day; **C)** retention test. Asteriscsdepict comparisons of the number of avoidances, following injections of the drug vs respective saline injections into CA1 area, ***P≤0.001; circles depict comparisons of the number of avoidances, following injections into the left vs right-side. n=6. Means (± S.E.M.) are presented.

Fig. 2 (A, B). Effects of Ang II (0,5µg) and losartan (100 µg)microinjectedunilaterally into the left or right CA1 hippocampal area ofOBX rats on the latent time (step through). **A)** 3rd hour. **B)** 24th hour.***P≤0.001; Asteriscsdepict comparisons of the latent time (sec) following injections of the drugs vs respective saline injections intoCA1areas; circles depict comparisons of the latent time (sec), following injections into the left vs right-side. n=8. Means (± S.E.M.) are presented.